Autem Therapeutics

Autem Therapeutics is a privately held oncology therapeutic and bioelectric med-tech company headquartered in Hanover NH, USA that is developing a novel, non-invasive, and non-toxic pan-cancer treatment platform targeting hepatocellular carcinoma (HCC), glioblastoma (GBM) and other solid tumors. The company has received FDA breakthrough designation for its device for the treatment of advanced HCC patients. The AutEMsys device delivers personalized, amplitude-modulated electromagnetic frequencies (AM-EMF) and based on early clinical feasibility studies shows promise in shrinking cancerous tumors, enhancing quality of life, and extending survival in early and advanced stage cancer patient populations. Autem Therapeutics anticipates approval of FDA Investigational Device Exemptions (IDE) to initiate clinical trials in HCC and GBM in the second half of 2025.